1
|
Górska A, Jabłońska E, Reszka E, Niedoszytko M, Lange M, Gruchała‐Niedoszytko M, Jarczak J, Strapagiel D, Górska‐Ponikowska M, Bastian P, Pelikant‐Małecka I, Kalinowski L, Nedoszytko B. DNA methylation profile in patients with indolent systemic mastocytosis. Clin Transl Allergy 2021; 11:e12074. [PMID: 34754417 PMCID: PMC8561632 DOI: 10.1002/clt2.12074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 09/21/2021] [Accepted: 09/27/2021] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND Mastocytosis is a clinically heterogeneous, usually acquired disease of the mast cells with a survival time that depends on the onset of the disease and ranges from skin-limited to systemic disease, including indolent and more aggressive variants. The crucial element in pathogenesis is the presence of oncogenic KIT somatic mutation D816V. Further epigenetic alterations are responsible for regulating the expression of genes. It is essential to identify indicators of disease progression, and the specific clinical picture to establish an appropriate therapeutic strategy. OBJECTIVE The aim of this study was to analyze the relation of mastocytosis symptoms and epigenetic changes, and to identify epigenetic predictors of the disease. METHODS Global DNA methylation profile analysis was performed in peripheral blood collected from 73 patients with indolent systemic mastocytosis (ISM) and 43 healthy adult volunteers. Levels of 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) were determined using an ELISA-based method, while the methylation of the Alu and LINE-1 repeats were assayed with the quantitative methylation-specific PCR technique. A questionnaire interview was conducted among the study participants to collect data on possible epigenetic modifiers. Additionally, the methylation profile was compared between three human mast cell lines: ROSA KIT D816V, ROSA KIT WT, and HMC-1.1 KIT V560G, in order to assess the association between KIT mutations and methylation profile. RESULTS A significantly lower level of DNA hydroxymethylation (5-hmC) in the blood was found in patients with ISM as compared to the controls (0.022% vs. 0.042%, p = 0.0001). Differences in the markers of global DNA methylation (5-mC, Alu, LINE-1) were not statistically significant, although they did indicate generally higher DNA methylation in patients with mastocytosis. The 5-hmC level was significantly associated with allergy (p = 0.011) in patients with ISM, showing a higher level of 5-hmC in patients with allergy as compared to patients without allergy. The in vitro study revealed significant differences between the studied cell lines at the level of 5-mC, Alu, and LINE-1. CONCLUSIONS This study confirms that epigenetic changes are involved in mastocytosis, and suggests that allergy may be an important epigenetic modifier of the disease. A possible association between KIT mutations and methylation status observed in human mast cell lines requires further investigation in human studies. CLINICAL IMPLICATIONS Epigenetic alterations are involved in mastocytosis pathology. The possible role of allergy as an important epigenetic modifier suggests the more impaired function of mast cells in ISM patients without allergy. CAPSULE SUMMARY Decreased DNA demethylation in the blood DNA of patients with ISM confirms that epigenetic alterations are involved in mastocytosis pathology. We observed a possible role of allergy as an important epigenetic modifier. There is a possible association between KIT mutations and the methylation status observed in human mast cell lines.
Collapse
Affiliation(s)
| | - Ewa Jabłońska
- Department of Translational ResearchNofer Institute of Occupational MedicineLodzPoland
| | - Edyta Reszka
- Department of Translational ResearchNofer Institute of Occupational MedicineLodzPoland
| | | | - Magdalena Lange
- Department of Dermatology, Venerology and AllergologyMedical University of GdanskGdanskPoland
| | | | - Justyna Jarczak
- Department of Molecular BiophysicsUniversity of LodzLodzPoland
| | | | | | - Paulina Bastian
- Department of Medical ChemistryMedical University of GdanskGdanskPoland
| | | | - Leszek Kalinowski
- Department of Clinical AnalyticsMedical University of GdanskGdanskPoland
| | - Bogusław Nedoszytko
- Department of Dermatology, Venerology and AllergologyMedical University of GdanskGdanskPoland
- Invicta Fertility and Reproductive CenterMolecular LaboratorySopotPoland
| |
Collapse
|
2
|
Agopian J, Da Costa Q, Nguyen QV, Scorrano G, Kousteridou P, Yuan M, Chelbi R, Goubard A, Castellano R, Maurizio J, Teodosio C, De Sepulveda P, Asara JM, Orfao A, Hermine O, Dubreuil P, Brenet F. GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness. Blood 2021; 138:1590-1602. [PMID: 33974006 DOI: 10.1182/blood.2020008948] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Accepted: 05/03/2021] [Indexed: 11/20/2022] Open
Abstract
Systemic mastocytosis (SM) is a KIT-driven hematopoietic neoplasm characterized by the excessive accumulation of neoplastic mast cells (MCs) in various organs and, mainly, the bone marrow (BM). Multiple genetic and epigenetic mechanisms contribute to the onset and severity of SM. However, little is known to date about the metabolic underpinnings underlying SM aggressiveness, which has thus far impeded the development of strategies to leverage metabolic dependencies when existing KIT-targeted treatments fail. Here, we show that plasma metabolomic profiles were able to discriminate indolent from advanced forms of the disease. We identified N-acetyl-d-glucosamine (GlcNAc) as the most predictive metabolite of SM severity. High plasma levels of GlcNAc in patients with advanced SM correlated with the activation of the GlcNAc-fed hexosamine biosynthesis pathway in patients BM aspirates and purified BM MCs. At the functional level, GlcNAc enhanced human neoplastic MCs proliferation and promoted rapid health deterioration in a humanized mouse model of SM. In addition, in the presence of GlcNAc, immunoglobulin E-stimulated MCs triggered enhanced release of proinflammatory cytokines and a stronger acute response in a mouse model of passive cutaneous anaphylaxis. Mechanistically, elevated GlcNAc levels promoted the transcriptional accessibility of chromatin regions that contain genes encoding mediators of receptor tyrosine kinases cascades and inflammatory responses, thus leading to a more aggressive phenotype. Therefore, GlcNAc is an oncometabolite driver of SM aggressiveness. This study suggests the therapeutic potential for targeting metabolic pathways in MC-related diseases to manipulate MCs effector functions.
Collapse
Affiliation(s)
- Julie Agopian
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
- French Reference Center for Mastocytosis (CEREMAST), Paris, France
| | - Quentin Da Costa
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
| | - Quang Vo Nguyen
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
| | - Giulia Scorrano
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
| | - Paraskevi Kousteridou
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
| | - Min Yuan
- Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Rabie Chelbi
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
- Inovarion, Paris, France
| | - Armelle Goubard
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
| | - Remy Castellano
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
| | - Julien Maurizio
- Centre d'Immunologie de Marseille-Luminy (CIML), INSERM U631, CNRS UMR 6102, Aix-Marseille Université, Marseille, France
| | - Cristina Teodosio
- Department of Immunohematology, Leiden University Medical Center, ZC Leiden, The Netherlands
| | - Paulo De Sepulveda
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
| | - John M Asara
- Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Alberto Orfao
- Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), Centro de Investigación Biomédica en Red Cáncer (CIBERONC), University of Salamanca, Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain
- Spanish Network on Mastocytosis (REMA), Toledo, Spain; and
| | - Olivier Hermine
- French Reference Center for Mastocytosis (CEREMAST), Paris, France
- Institut Imagine, INSERM U1163, CNRS Equipe de Recherche Labelisée (ERL) 8654, Paris Université, Service d'Hématologie Clinique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Patrice Dubreuil
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
- French Reference Center for Mastocytosis (CEREMAST), Paris, France
| | - Fabienne Brenet
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, Unité Mixte de Recherche (UMR) 258 Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université, Institut Paoli-Calmettes, Equipe Labellisée Ligue Contre le Cancer, Marseille, France
- French Reference Center for Mastocytosis (CEREMAST), Paris, France
| |
Collapse
|
3
|
Reszka E, Jabłońska E, Wieczorek E, Valent P, Arock M, Nilsson G, Nedoszytko B, Niedoszytko M. Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis. Int J Mol Sci 2021; 22:2964. [PMID: 33803981 PMCID: PMC7999363 DOI: 10.3390/ijms22062964] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Revised: 03/10/2021] [Accepted: 03/12/2021] [Indexed: 12/23/2022] Open
Abstract
Systemic mastocytosis (SM) is a hematologic neoplasm with abnormal accumulation of mast cells in various organ systems such as the bone marrow, other visceral organs and skin. So far, only little is known about epigenetic changes contributing to the pathogenesis of SM. In the current article, we provide an overview of epigenetic changes that may occur and be relevant to mastocytosis, including mutations in genes involved in epigenetic processes, such as TET2, DNMT3A and ASXL1, and global and gene-specific methylation patterns in neoplastic cells. Moreover, we discuss methylation-specific pathways and other epigenetic events that may trigger disease progression in mast cell neoplasms. Finally, we discuss epigenetic targets and the effects of epigenetic drugs, such as demethylating agents and BET-targeting drugs, on growth and viability of neoplastic mast cells. The definitive impact of these targets and the efficacy of epigenetic therapies in advanced SM need to be explored in future preclinical studies and clinical trials.
Collapse
Affiliation(s)
- Edyta Reszka
- Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, 91-348 Lodz, Poland; (E.J.); (E.W.)
| | - Ewa Jabłońska
- Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, 91-348 Lodz, Poland; (E.J.); (E.W.)
| | - Edyta Wieczorek
- Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, 91-348 Lodz, Poland; (E.J.); (E.W.)
| | - Peter Valent
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria;
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria
| | - Michel Arock
- Department of Hematological Biology, Pitié-Sapêtrière Hospital, Sorbonne University, 75013 Paris, France;
| | - Gunnar Nilsson
- Division of Immunology and Allergy, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, SE-171 76 Stockholm, Sweden;
| | - Bogusław Nedoszytko
- Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 80-211 Gdansk, Poland;
- Invicta Fertility and Reproductive Center, Molecular Laboratory, Polna 64, 81-740 Sopot, Poland
| | - Marek Niedoszytko
- Department of Allergology, Medical University of Gdansk, 80-211 Gdansk, Poland
| |
Collapse
|
4
|
Du Y, Wang Y, Hu X, Liu J, Diao J. Single‐molecule quantification of 5‐methylcytosine and 5‐hydroxymethylcytosine in cancer genome. VIEW 2020. [DOI: 10.1002/viw2.9] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Affiliation(s)
- Yang Du
- Department of BiotherapyCancer CenterState Key Laboratory of BiotherapyWest China HospitalSichuan University Chengdu China
- Department of Cancer BiologyUniversity of Cincinnati College of Medicine Cincinnati Ohio USA
| | - Yongyao Wang
- Department of Cancer BiologyUniversity of Cincinnati College of Medicine Cincinnati Ohio USA
| | - Xiao Hu
- Department of Cancer BiologyUniversity of Cincinnati College of Medicine Cincinnati Ohio USA
| | - Jiyan Liu
- Department of BiotherapyCancer CenterState Key Laboratory of BiotherapyWest China HospitalSichuan University Chengdu China
| | - Jiajie Diao
- Department of Cancer BiologyUniversity of Cincinnati College of Medicine Cincinnati Ohio USA
| |
Collapse
|
5
|
Mervis JS, McGee JS. DNA methylation and inflammatory skin diseases. Arch Dermatol Res 2019; 312:461-466. [PMID: 31696298 DOI: 10.1007/s00403-019-02005-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Revised: 08/25/2019] [Accepted: 10/19/2019] [Indexed: 12/29/2022]
Abstract
Epigenetics is the study of heritable changes in gene expression that do not originate from alternations in the DNA sequence. Epigenetic modifications include DNA methylation, histone modification, and gene silencing via the action of microRNAs. Epigenetic dysregulation has been implicated in many disease processes. In the field of dermatology, epigenetic regulation has been extensively explored as a pathologic mechanism in cutaneous T-cell lymphoma (CTCL), which has led to the successful development of epigenetic therapies for CTCL. In recent years, the potential role of epigenetic regulation in the pathogeneses of inflammatory skin diseases has gained greater appreciation. In particular, epigenetic changes in psoriasis and atopic dermatitis have been increasingly studied, with DNA methylation the most rigorously investigated to date. In this review, we provide an overview of DNA methylation in inflammatory skin diseases with an emphasis on psoriasis and atopic dermatitis.
Collapse
Affiliation(s)
- Joshua S Mervis
- Department of Dermatology, Boston University School of Medicine, 609 Albany Street, J-505, Boston, MA, 02118, USA
| | - Jean S McGee
- Department of Dermatology, Boston University School of Medicine, 609 Albany Street, J-505, Boston, MA, 02118, USA.
| |
Collapse
|
6
|
Abstract
Mast cells are tissue-resident, innate immune cells present in most tissues of the body and are important effector and immunomodulatory cells. Differentiated mast cells typically are characterized by the surface expression of the receptors KIT and FcεRI, the latter especially being important for stimulation through IgE antibodies, although these cells have the ability to respond to a wide variety of environmental signals, to which they can variably react by releasing pre-stored or
de novo–synthesized mediators or both. Since mast cells terminate their differentiation in their tissue of residence in response to specific microenvironmental cues, each tissue may comprise unique mast cell subtypes, and responses are tailored to the danger signals that are likely to be encountered in each anatomical location. From a transcriptional point of view, these cells therefore must be endowed with epigenetic and transcriptional programs that allow them to maintain a stable identity and at the same time allow sufficient plasticity to adapt to different environmental challenges. In this commentary, we highlight some of the recent findings that advanced our understanding of the transcriptional and epigenetic programs regulating mast cell functions.
Collapse
Affiliation(s)
- Silvia Monticelli
- Institute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland
| | - Cristina Leoni
- Institute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland
| |
Collapse
|
7
|
Qing Y, Tian Z, Bi Y, Wang Y, Long J, Song CX, Diao J. Quantitation and mapping of the epigenetic marker 5-hydroxymethylcytosine. Bioessays 2017; 39. [DOI: 10.1002/bies.201700010] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Ying Qing
- Department of Cancer Biology; University of Cincinnati College of Medicine; Cincinnati OH USA
| | - Zhiqi Tian
- Department of Cancer Biology; University of Cincinnati College of Medicine; Cincinnati OH USA
- Center for Mitochondrial Biology and Medicine; The Key Laboratory of Biomedical Information Engineering of Ministry of Education; School of Life Science and Technology Xi'an Jiaotong University; Xi'an China
| | - Ying Bi
- Ludwig Institute for Cancer Research, Nuffield Department of Medicine; University of Oxford; Oxford UK
| | - Yongyao Wang
- Department of Cancer Biology; University of Cincinnati College of Medicine; Cincinnati OH USA
- Center for Mitochondrial Biology and Medicine; The Key Laboratory of Biomedical Information Engineering of Ministry of Education; School of Life Science and Technology Xi'an Jiaotong University; Xi'an China
| | - Jiangang Long
- Center for Mitochondrial Biology and Medicine; The Key Laboratory of Biomedical Information Engineering of Ministry of Education; School of Life Science and Technology Xi'an Jiaotong University; Xi'an China
| | - Chun-Xiao Song
- Ludwig Institute for Cancer Research, Nuffield Department of Medicine; University of Oxford; Oxford UK
- Target Discovery Institute; Nuffield Department of Medicine; University of Oxford; Oxford UK
| | - Jiajie Diao
- Department of Cancer Biology; University of Cincinnati College of Medicine; Cincinnati OH USA
| |
Collapse
|
8
|
Abstract
DNA methylation and specifically the DNA methyltransferase enzyme DNMT3A are involved in the pathogenesis of a variety of hematological diseases and in regulating the function of immune cells. Although altered DNA methylation patterns and mutations in DNMT3A correlate with mast cell proliferative disorders in humans, the role of DNA methylation in mast cell biology is not understood. By using mast cells lacking Dnmt3a, we found that this enzyme is involved in restraining mast cell responses to acute and chronic stimuli, both in vitro and in vivo. The exacerbated mast cell responses observed in the absence of Dnmt3a were recapitulated or enhanced by treatment with the demethylating agent 5-aza-2'-deoxycytidine as well as by down-modulation of Dnmt1 expression, further supporting the role of DNA methylation in regulating mast cell activation. Mechanistically, these effects were in part mediated by the dysregulated expression of the scaffold protein IQGAP2, which is characterized by the ability to regulate a wide variety of biological processes. Altogether, our data demonstrate that DNMT3A and DNA methylation are key modulators of mast cell responsiveness to acute and chronic stimulation.
Collapse
|
9
|
Molderings GJ. Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features. Transl Res 2016; 174:86-97. [PMID: 26880691 DOI: 10.1016/j.trsl.2016.01.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Revised: 01/02/2016] [Accepted: 01/04/2016] [Indexed: 02/08/2023]
Abstract
Systemic mast cell activation disease (MCAD) comprises disorders characterized by an enhanced release of mast cell mediators accompanied by a varying accumulation of dysfunctional mast cells. Within the last years, evidence has been presented that MCAD is a multifactorial polygenic determined disease with the KIT(D816V) mutation and its induced functional consequences considered as special case. The respective genes encode proteins for various signaling pathways, epigenetic regulators, the RNA splicing machinery, and transcription factors. Transgenerational transmission of MCAD appears to be quite common. The basics of the molecular mechanisms underlying predisposition of the disease, that is, somatic and germline mutations and the contribution of epigenetic processes have become identifiable. The aim of the present review is to present and discuss available genetic, epigenetic and epidemiological findings, and to present a model of MCAD pathogenesis.
Collapse
Affiliation(s)
- Gerhard J Molderings
- Institute of Human Genetics, University Hospital of Bonn, Sigmund-Freud-Strasse 25, D-53127 Bonn, Germany.
| |
Collapse
|
10
|
Montagner S, Leoni C, Emming S, Della Chiara G, Balestrieri C, Barozzi I, Piccolo V, Togher S, Ko M, Rao A, Natoli G, Monticelli S. TET2 Regulates Mast Cell Differentiation and Proliferation through Catalytic and Non-catalytic Activities. Cell Rep 2016; 15:1566-1579. [PMID: 27160912 DOI: 10.1016/j.celrep.2016.04.044] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Revised: 03/08/2016] [Accepted: 04/07/2016] [Indexed: 12/13/2022] Open
Abstract
Dioxygenases of the TET family impact genome functions by converting 5-methylcytosine (5mC) in DNA to 5-hydroxymethylcytosine (5hmC). Here, we identified TET2 as a crucial regulator of mast cell differentiation and proliferation. In the absence of TET2, mast cells showed disrupted gene expression and altered genome-wide 5hmC deposition, especially at enhancers and in the proximity of downregulated genes. Impaired differentiation of Tet2-ablated cells could be relieved or further exacerbated by modulating the activity of other TET family members, and mechanistically it could be linked to the dysregulated expression of C/EBP family transcription factors. Conversely, the marked increase in proliferation induced by the loss of TET2 could be rescued exclusively by re-expression of wild-type or catalytically inactive TET2. Our data indicate that, in the absence of TET2, mast cell differentiation is under the control of compensatory mechanisms mediated by other TET family members, while proliferation is strictly dependent on TET2 expression.
Collapse
Affiliation(s)
- Sara Montagner
- Institute for Research in Biomedicine, Universita' della Svizzera italiana (USI), 6500 Bellinzona, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland
| | - Cristina Leoni
- Institute for Research in Biomedicine, Universita' della Svizzera italiana (USI), 6500 Bellinzona, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland
| | - Stefan Emming
- Institute for Research in Biomedicine, Universita' della Svizzera italiana (USI), 6500 Bellinzona, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland
| | - Giulia Della Chiara
- Department of Experimental Oncology, European Institute of Oncology (IEO), 20139 Milan, Italy
| | - Chiara Balestrieri
- Department of Experimental Oncology, European Institute of Oncology (IEO), 20139 Milan, Italy
| | - Iros Barozzi
- Department of Experimental Oncology, European Institute of Oncology (IEO), 20139 Milan, Italy
| | - Viviana Piccolo
- Department of Experimental Oncology, European Institute of Oncology (IEO), 20139 Milan, Italy
| | - Susan Togher
- La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
| | - Myunggon Ko
- La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA; School of Life Sciences, Ulsan National Institute of Science and Technology, UNIST-gil 50, Ulju-gun, Ulsan 689-798, Republic of Korea
| | - Anjana Rao
- La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
| | - Gioacchino Natoli
- Department of Experimental Oncology, European Institute of Oncology (IEO), 20139 Milan, Italy
| | - Silvia Monticelli
- Institute for Research in Biomedicine, Universita' della Svizzera italiana (USI), 6500 Bellinzona, Switzerland.
| |
Collapse
|